The phase I/II clinical trials of INO-4800（pGX9501） in the United States were conducted by our strategical partner Inovio. The Clinical data shows, pGX9501 is able to provide broad cross-reactive immune responses, including neutralizing antibodies and robust T cell responses(including CD8 and CD4).